{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:27:14Z","timestamp":1790260034511,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1126331"],"award-info":[{"award-number":["OPP1126331"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2\u201323\u2009months presenting with acute non-bloody diarrhoea who are dehydrated and\/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10\u2009mg\/kg or placebo once daily for 3\u2009days and followed-up for 180\u2009days. Primary efficacy endpoints are all-cause mortality during the 180\u2009days post-enrolment and change in linear growth 90\u2009days post-enrolment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03130114\">NCT03130114<\/jats:ext-link>\n                      . Registered on April 26 2017.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-019-3829-y","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T06:03:08Z","timestamp":1578895388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A double-blind placebo-controlled trial of azithromycin to reduce mortality and improve growth in high-risk young children with non-bloody diarrhoea in low resource settings: the Antibiotics for Children with Diarrhoea (ABCD) trial protocol"],"prefix":"10.1186","volume":"21","author":[{"name":"The ABCD study team","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"3829_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S1473-3099(18)30362-1","volume":"18","author":"GBD 2016 Diarrhoeal Diseases Collaborators","year":"2018","unstructured":"GBD 2016 Diarrhoeal Diseases Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18:1211\u201328.","journal-title":"Lancet Infect Dis"},{"key":"3829_CR2","unstructured":"World Health Organization. Integrated management of childhood illness. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43993\/9789241597289_eng.pdf?sequence=1. Accessed 22 June 2019."},{"issue":"9876","key":"3829_CR3","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(13)60319-0","volume":"381","author":"M Chopra","year":"2013","unstructured":"Chopra M, Mason E, Borrazzo J, Campbell H, Rudan I, Liu L, Black RE, Bhutta ZA. Ending of preventable deaths from pneumonia and diarrhoea: an achievable goal. Lancet. 2013;381(9876):1499\u2013506.","journal-title":"Lancet"},{"issue":"9888","key":"3829_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","volume":"382","author":"KL Kotloff","year":"2013","unstructured":"Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382(9888):209\u201322.","journal-title":"Lancet"},{"key":"3829_CR5","unstructured":"Platts-Mills JA, et al. Use of quantitative molecular diagnostic methods to assess the aetiology, burden, and clinical characteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL-ED cohort study. Lancet Global Health. 2018;6(12):e1309\u201318."},{"issue":"4","key":"3829_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/jpids\/piv037","volume":"5","author":"PB Pavlinac","year":"2016","unstructured":"Pavlinac PB, Denno DM, John-Stewart GC, Onchiri FM, Naulikha JM, Odundo EA, Hulseberg CE, Singa BO, Manhart LE, Walson JL. Failure of syndrome-based diarrhea management guidelines to detect Shigella infections in Kenyan children. J Pediatric Infect Dis Soc. 2016;5(4):366\u201374.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"3829_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/jpids\/piv028","volume":"5","author":"JM Pernica","year":"2016","unstructured":"Pernica JM, Steenhoff AP, Welch H, Mokomane M, Quaye I, Arscott-Mills T, Mazhani L, Lechiile K, Mahony J, Smieja M, Goldfarb DM. Correlation of clinical outcomes with multiplex molecular testing of stool from children admitted to hospital with gastroenteritis in Botswana. J Pediatric Infect Dis Soc. 2016;5(3):312\u20138.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"3829_CR8","first-page":"1207","volume":"78","author":"AL Rice","year":"2000","unstructured":"Rice AL, Sacco L, Hyder A, Black RE. Malnutrition as an underlying cause of childhood deaths associated with infectious diseases in developing countries. Bull World Health Organ. 2000;78:1207\u201321.","journal-title":"Bull World Health Organ"},{"issue":"11","key":"3829_CR9","doi-asserted-by":"publisher","first-page":"e0207743","DOI":"10.1371\/journal.pone.0207743","volume":"13","author":"AG Wasihun","year":"2018","unstructured":"Wasihun AG, Dejene TA, Teferi M, et al. Risk factors for diarrhoea and malnutrition among children under the age of 5 years in the Tigray Region of Northern Ethiopia. PLoS One. 2018;13(11):e0207743.","journal-title":"PLoS One"},{"key":"3829_CR10","volume-title":"Report of the 20th meeting of the WHO alliance for the global elimination of trachoma by 2020 Sydney, Australia","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Report of the 20th meeting of the WHO alliance for the global elimination of trachoma by 2020 Sydney, Australia. 2019."},{"key":"3829_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2009.1266","volume":"302","author":"TC Porco","year":"2009","unstructured":"Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009;302:962\u20138.","journal-title":"JAMA"},{"key":"3829_CR12","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1056\/NEJMoa1715474","volume":"378","author":"JD Keenan","year":"2018","unstructured":"Keenan JD, Bailey RL, West SK, et al. Azithromycin to reduce childhood mortality in sub-Saharan Africa. N Engl J Med. 2018;378:1583\u201392.","journal-title":"N Engl J Med"},{"key":"3829_CR13","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1817213","volume":"380","author":"JD Keenan","year":"2019","unstructured":"Keenan JD, Arzika AM, Maliki R, et al. Longer-term assessment of azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;380:2207\u201314.","journal-title":"N Engl J Med"},{"key":"3829_CR14","volume-title":"Pocket book of hospital care for children. Guidelines for the management of common childhood illnesses","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Pocket book of hospital care for children. Guidelines for the management of common childhood illnesses. Geneva: World Health Organization; 2013."},{"key":"3829_CR15","unstructured":"World Health Organization. Measuring a child\u2019s growth. https:\/\/www.who.int\/childgrowth\/training\/module_b_measuring_growth.pdf. Accessed 22 June 2019."},{"issue":"1","key":"3829_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1185\/03007995.2011.639355","volume":"28","author":"AK Lako\u0161","year":"2012","unstructured":"Lako\u0161 AK, Panger\u010di\u0107 A, Ga\u0161pari\u0107 M, Kukuruzovi\u0107 MM, Kova\u010di\u0107 D, Bar\u0161i\u0107 B. Safety and effectiveness of azithromycin in the treatment of respiratory infections in children. Curr Med Res Opin. 2012;28(1):155\u201362.","journal-title":"Curr Med Res Opin"},{"key":"3829_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/ije\/dyu062","volume":"43","author":"JC Seidman","year":"2014","unstructured":"Seidman JC, Coles CL, Silbergeld EK, et al. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Int J Epidemiol. 2014;43:1105\u201313.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"3829_CR18","doi-asserted-by":"publisher","first-page":"9168","DOI":"10.1038\/s41598-017-06862-0","volume":"7","author":"EPK Parker","year":"2017","unstructured":"Parker EPK, Praharaj I, John J, Kaliappan SP, Kampmann B, Kang G, Grassly NC. Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India. Sci Rep. 2017;7(1):9168.","journal-title":"Sci Rep"},{"issue":"1","key":"3829_CR19","doi-asserted-by":"publisher","first-page":"010603","DOI":"10.7189\/jogh.06.010603","volume":"6","author":"AK Koffi","year":"2016","unstructured":"Koffi AK, Maina A, Yaroh AG, Habi O, Bensa\u00efd K, Kalter HD. Social determinants of child mortality in Niger: results from the 2012 national verbal and social autopsy study. J Glob Health. 2016;6(1):010603.","journal-title":"J Glob Health"},{"key":"3829_CR20","volume-title":"Group sequential methods with applications to clinical trials","author":"C Jennison","year":"2000","unstructured":"Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton: Chapman & Hall\/CRC; 2000."},{"key":"3829_CR21","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1811400","volume":"380","author":"D Chandramohan","year":"2019","unstructured":"Chandramohan D, Dicko A, Zongo I, et al. Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med. 2019;380:2197\u2013206.","journal-title":"N Engl J Med"},{"issue":"1","key":"3829_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2471\/BLT.16.176123","volume":"95","author":"ET Rogawski","year":"2017","unstructured":"Rogawski ET, Platts-Mills JA, Seidman JC, et al. Use of antibiotics in children younger than two years in eight countries. Bull World Health Organ. 2017;95(1):49\u201361.","journal-title":"Bull World Health Organ"},{"issue":"7443","key":"3829_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/bmj.38049.490255.DE","volume":"328","author":"ISCAP Study Group","year":"2004","unstructured":"ISCAP Study Group. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ. 2004;328(7443):791.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3829-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T20:21:28Z","timestamp":1610396488000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3829-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3829-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.12514\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.12514\/v2","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"5 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial has been approved by the WHO Ethics Review Committee and by the Ethics Committees of all participating sites in the seven countries \u2013 Bangladesh (Ethical Review Committee of the International Centre for Diarrhoeal Disease Research), India (Institutional Ethics Committee, Subharti Medical College & Hospital, Swami Vivekanand Subharti University), Kenya (Kenya Medical Research Institute Ethical Review Committee and the University of Washington Institutional Review Board), Malawi (University of Malawi College of Medicine Research Ethics Committee), Mali (Comite d\u2019Ethique de la FMPOS (ERC at USTTB), University of Maryland, Baltimore Research Ethics Committee), Pakistan (Aga Khan University, Ethical Review Committee), Tanzania (Muhimbili University of Health and Allied Sciences Senate Research and Publications Committee; Tanzanian Food and Drug Administration; National Institute for Medical Research), and Boston (Boston Children\u2019s Hospital Institutional Review Board). Each updated version of the approved protocol will be submitted to the ethical committees above.Written informed consent (from parents\/caregivers) is obtained by study staff before any trial procedures are carried out and participant confidentiality is maintained throughout the trial in line with the standard ICH-GCP principles.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}